viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals shines under broker spotlight

Paradigm has been attracting the attention of brokers.

Baker Young has a Buy Recommendation on the stock

Paradigm Biopharmaceuticals (ASX:PAR) is focused on repurposing the historic drug PPS (Pentosan Polysulfate Sodium) as a potential new treatment for Bone Marrow Edema (BME) lesions following traumatic injury.

The company has recently come under the spotlight of brokers.

Baker Young has a Buy Recommendation on the stock with a $1.16 per share price target, while DJ Carmichael applying a Speculative Buy and a risked valuation of $1.32 per share.

Paradigm last traded at a significant discount to these prices, at $0.40 per share.

Following are some key finding from the broker reports.

Baker Young

Hay fever Phase II Trial Nears Completion – Results Readout Q2/Q3 CY2017

We maintain coverage of Paradigm with a BUY recommendation and have increased our valuation to $1.16 per share due to Phase II hay fever trial nearing completion.

Our valuation is derived from using a combination of probability weighted DCF methodology ($1.18) and peer group valuation ($1.14 implied PAR share price).

Our target price of $1.16 per share sits in the midpoint of our valuation range.

DJ Carmichael

Phase 2 hay fever clinical trial on schedule and budget

We maintain our Speculative Buy recommendation. We stress that PAR is significantly under-valued compared to peers who have compounds undergoing Phase II trials.

We believe a successful outcome will be a major catalytic event for PAR and is likely to initiate interest from big pharma who are looking to replace revenues from drugs going off-patent.

Our valuation remains between A$120M and A$152M which corresponds to share price of A$1.18 and A$1.50 respectively, or a mid-point of $1.34 per share.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 1.69 AUD

Market: ASX
Market Cap: $334.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


2 min read